Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Camlipixant ER vs IR in Healthy Subjects
NCT05570539Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of camlipixant in chronic cough (2 arms), sponsored by GSK. Primary endpoints: Maximum Observed Plasma Drug Concentration, Minimum Observed Plasma Drug Concentration and 2 more. Started Oct 2022; status: completed.
02
Drugs
camlipixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT05570539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570539.